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AbstrACt
Introduction Myalgic encephalomyelitis/chronic fatigue 
syndrome (ME/CFS) is a chronic disease involving central 
nervous system and immune system disorders, as well 
as cardiovascular abnormalities. ME/CFS is characterised 
by severe chronic fatigue lasting for at least 6 months, 
including clinical symptoms such as tender cervical or 
axillary lymph nodes, muscle pain, joint pain without 
swelling or redness, post-exertional malaise for more 
than 24 hours and unrefreshing sleep. Studies on the 
epidemiology of ME/CFS in Europe only include single 
countries and, therefore, the prevalence and incidence 
of ME/CFS in Europe (as a whole) is unknown. One 
of the purposes of the European Network on ME/CFS 
(EUROMENE; European Union-funded COST Action; 
Reference number: 15111) is to address this gap in 
knowledge. We will systematically review the literature 
reporting figures from European countries to provide a 
robust summary and identify new challenges.
Methods and analysis We will systematically search the 
literature databases Scopus, PubMed and Web of Science 
for studies published in the last 10 years (ie, after 2007). 
No language restriction will be applied. Two independent 
reviewers will search, screen and select studies as well 
as extract data about their main characteristics and 
evaluate their methodological and reporting quality. When 
disagreements emerge, the reviewers will discuss to reach 
a consensus. We plan to produce a narrative summary 
of our findings as we anticipate that studies are scarce 
and heterogeneous. The possibility of performing meta-
analyses will be discussed in a EUROMENE meeting.
Ethics and dissemination Ethical approval is not 
required as only publicly available data will be included. 
Findings will be described in EUROMENE reports, published 
in peer-reviewed journal(s) and presented at conferences. 
The findings will be also communicated to policy-makers, 
healthcare providers, people with ME/CFS and other 
sections of society through regular channels including the 
mass-media.
PrOsPErO registration number CRD42017078688
IntrOduCtIOn 
Myalgic encephalomyelitis/chronic fatigue 
syndrome (ME/CFS) has heterogeneous 
clinical features and is characterised by severe 
fatigue lasting for at least 6 months that is 
medically unexplained and not relieved 
by resting.1 Consequently, ME/CFS often 
strengths and limitations of this study
 ► The main strengths of this protocol rely on its care-
fully designed search strategy, inclusion and exclu-
sion criteria, and time-span coverage.
 ► The search strategy will address the potential EU 
studies published in non-English national languag-
es, and we will include currently accepted myalgic 
encephalomyelitis/chronic fatigue syndrome (ME/
CFS) case definitions, to minimise selection bias.
 ► Studies based on self-report will be excluded, and 
the search time of 10 years will enable us to picture 
the ME/CFS occurrence in Europe.
 ► The European Network on ME/CFS (EUROMENE), a 
network of established researchers on ME/CFS, will 
conduct the proposed systematic review which can 
increase credibility and reliability of the findings.
 ► A potential limitation of this review may be a small 
number of studies available and their potential high 
heterogeneity.
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imposes a huge burden on daily life with negative impacts 
on health-related quality of life, labour status, and social 
and familial relationships.2–4 Societal disbeliefs may add 
to the burden for people with ME/CFS.3 5 
For several reasons, ME/CFS is a challenge for scien-
tists. First, to date, the features of ME/CFS have been 
poorly defined. For instance, an intense physical discom-
fort (ie, malaise) along with flares of ME/CFS symp-
toms (lasting for longer than 24 hours) is observed after 
minimum physical exertion.6 However, whether post-ex-
ertional malaise is a distinctive feature of ME/CFS is not 
yet fully agreed.7 Second, related to the lack of consensus 
on its defining features, a large number of disparate 
criteria for the diagnosis of ME/CFS are currently used 
worldwide.8 Indeed, the most common scenario is to 
diagnose ME/CFS after exclusion of other diseases.4 9–13 
Third, as different diagnostic criteria are used, ME/
CFS prevalence and incidence figures are highly vari-
able across studies. For instance, within an Icelandic 
study,14 the prevalence of ME/CFS ranged from 0% to 
5% by means of the Lloyd et al15 or Holmes et al16 criteria, 
respectively.
To address the above-mentioned caveats and others, it 
is imperative to understand ME/CFS comprehensively. 
With this purpose, the European Network on ME/CFS 
(EUROMENE) was established. This (EU-funded COST 
Action; Reference number: 15111) multidisciplinary 
network involves patients, stakeholders, researchers, clini-
cians and industry. We intend to align ME/CFS research 
within the established landscape of European biomed-
ical research by developing additional proposals to the 
new H2020 and further Framework programme collab-
orative research projects. Further information about the 
EUROMENE network is available at http://www. cost. eu/ 
COST_ Actions/ ca/ CA15111 and http://www. euromene. 
eu/.
EUROMENE consists of six closely coordinated 
working groups. Working group 1 focuses on the epide-
miology of ME/CFS and leads the European Epidemi-
ological Study for ME/CFS (Euro-EpiME study). One 
specific aim of this study is to estimate the prevalence and 
incidence of ME/CFS in Europe. As a first step, we will 
systematically review the available literature from Euro-
pean countries in order to provide a robust summary and 
identify new challenges in the field. It seems likely that 
more data on the prevalence and incidence of ME/CFS 
will be needed, both for Europe as a whole and within the 
European countries. Previously, systematic reviews have 
been conducted including studies from many parts of 
the world.17–19 However, these previous reviews: (1) were 
conducted more than 5 years ago,20 (2) did not report the 
incidence of ME/CFS and (3) did not include children or 
adolescents.
Objective
We aim to conduct a systematic review and, if possible, 
meta-analyses to determine the prevalence and incidence 
of ME/CFS in Europe.
review question
1. What is the prevalence of ME/CFS in Europe?
2. What is the incidence of ME/CFS in Europe?
MEthOds
Inclusion criteria
1. Studies reporting either the prevalence or incidence 
of ME/CFS, including any of the following clinical 
diagnostic criteria: CDC-1994,9 Canadian Consensus 
Criteria,1 London Criteria,21 International Consensus 
Criteria10 or Institute of Medicine criteria,22 irrespec-
tive of age groups.
2. Studies from European countries.
3. Studies in community or primary care settings.
Exclusion criteria
1. Studies without primary data (eg, reviews).
2. Studies conducted in biased samples (eg, vaccines, vi-
rus infection, veterans).
3. Studies based on self-report of the diagnosis of ME/
CFS.
4. Studies with an inappropriate case definition (eg, CFS-
like illness or other clinical criteria, such as the Oxford 
criteria due to lack of specificity).
5. Duplicate reports. When populations are overlapping, 
the study with the largest sample size will be included.
6. Studies published more than 10 years ago (ie, before 
2008).
No language restriction will be applied.
search strategy for identifying relevant studies
The search strategy will consist of two stages: a primary 
systematic literature search on three electronic databases 
and a complementary search.
The primary systematic literature search on electronic databases
Two independent reviewers (FE-L and JC-M) will perform 
a primary electronic search in PubMed, Scopus and Web 
Table 1 The primary systematic literature search strategy 
on the electronic databases
Database Search terms combination
Scopus ({epidemiology} OR {prevalence} OR 
{incidence}) AND ({chronic fatigue 
syndrome} OR {myalgic encephalomyelitis} 
OR {CFS/ME} OR {ME/CFS})
PubMed ("Fatigue Syndrome, Chronic"[Mesh] 
AND (("Incidence" [Mesh] OR 
"Epidemiology"[Mesh] OR "epidemiology" 
[Subheading] OR "Prevalence "[Mesh] OR 
"Cross-Sectional Studies "[Mesh]))
Web of Science ("epidemiology" OR "prevalence" OR 
"incidence") AND ("chronic fatigue 
syndrome" OR "myalgic encephalomyelitis" 
OR "CFS/ME" OR " ME/CFS")
Mesh, medical subject headings.
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of Science on 9 January 2018. Table 1 shows the search 
strategy.
The complementary search
We will conduct a twofold complementary search as 
follows: first, we will perform a backward (by checking 
reference lists) and forward (by checking citations) 
search of the works included in the present review; and 
second, grey literature will be addressed by contacting—
via email—all the members of EUROMENE to provide, 
if available, prevalence rates, incidence rates or both of 
ME/CFS in their countries according to national regis-
ters, publications in their own languages or any other 
publicly accessible source.
selection of studies for inclusion to the review
Two independent researchers (FE-L and JC-M) will 
screen records retrieved by the electronic search by titles/
abstracts or full text of works for identifying potential 
studies and their suitability. When disagreements emerge 
between the two independent researchers, consensus will 
be obtained through discussion or when required, the 
opinion of a third researcher (IJB) will be considered.
Assessment of methodological quality and reporting of data
The methodological quality of the eligible studies will be 
evaluated with the Joanna Briggs Institute-Checklist for 
Prevalence Studies.23 Before applying it, six members of 
the research team (ie, FE-L, LN, JA, SS, EL and MM) will 
develop an agreed appraisal of the tool. This appraisal 
will be published with the review as supplementary infor-
mation. The reporting quality of the eligible studies will 
be evaluated using the Strengthening the Reporting of 
Observational Studies in Epidemiology checklist.24 Two 
independent researchers (ie, AI and XW) will evaluate 
the methodological and reporting quality of the included 
works. When controversies emerge, studies will be 
discussed with two other members of the team in order 
to reach a consensus (ie, EBS and DP for methodological 
and reporting quality, respectively). The quality assess-
ment will be considered when discussing the findings.
data extraction and management
To manage the retrieved records from the electronic 
search, we will use the Mendeley Desktop. Two indepen-
dent researchers (FE-L and AI) will extract the following 
relevant data from the included studies: reference 
(authors and year of publication), country (city or region 
when relevant), design (ie, general population online 
survey), total sample size (n and % of women, n and % 
of migrants), age range, setting (eg, primary care), case 
definition (ie, diagnosis criteria), dates of data collection, 
overall prevalence and/or incidence and prevalence 
and/or incidence by gender and age groups (when avail-
able). When discrepancies emerge in the coding between 
the two researchers’ results, these will be discussed 
with another members of the team (ie, NS) to reach a 
consensus.
data synthesis and analysis
We anticipate that studies on the prevalence and inci-
dence of ME/CFS in Europe will prove to be scarce 
and heterogeneous. The preliminary findings of the 
review will be presented in a EUROMENE meeting (ie, 
September 2018, in London, UK) where we will discuss 
the appropriateness of performing meta-analyses.
A narrative (descriptive) synthesis is planned if 
meta-analyses are not feasible. We will pay special atten-
tion to possible factors related to heterogeneity of the 
findings in order to find patterns that should be consid-
ered in future research. For instance, we will discuss 
whether the prevalence or incidence of ME/CFS differ 
according to the case definition used to examine the 
figures. Attention will be also paid to the characteristics 
of the studied populations (eg, age group, gender).
We will undertake meta-analyses only where pooling of 
quantitative data is possible. The meta regression analysis 
will be performed to investigate the sources of heteroge-
neity of any ME/CFS pooled prevalence and incidence 
estimate. The I2 statistic will be used to investigate the 
heterogeneity. I2 of 25%, 50% and 75% will be appraised 
as low, moderate and high, respectively.25
Presentation and reporting of results
We will report the findings of the present literature review 
in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses statement.26 A flow 
diagram (figure 1) will illustrate the process of study selec-
tion from retrieved records to included studies. For trans-
parency purposes, supplementary files will show which 
studies were excluded at every stage of the review. If the 
present protocol needs amendments, they will be publicly 
available along with their rationale on the EUROMENE 
website (http://www. euromene. eu/).
In accordance with the data extraction, a table will show 
the main characteristics of the studies included. Informa-
tion on the quality of the methodology and reporting of 
the studies will also be available.
If meta-analyses are performed, we plan using compre-
hensive meta-analysis to combine data of prevalence or 
incidence from different studies to estimate the mean 
effect. We will select an appropriate model in terms of 
studies that we include and calculate pooled ME/CFS 
prevalence and incidence. We will compare the results 
of random-effects and fixed-effect meta-analyses in sensi-
tivity analyses.
Ethics and dissemination
The findings of this systematic review will address a 
specific aim of the European network EUROMENE (ie, 
to summarise the available data of the prevalence and 
incidence of ME/CFS in Europe). The findings will be 
included in EUROMENE reports published in paper(s) 
in peer-reviewed journal(s) and presented at conferences 
and meetings.
The findings of the present systematic review will 
be widely communicated to society using mass media 
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(eg, interviews on radio, newspaper, television and the 
internet). Since our findings may have an impact on 
policy and healthcare practice, we will also present them 
to policy-makers and healthcare providers.
Patient and public involvement
EUROMENE is multidisciplinary network cooperating 
with patient organisations via Web platform. Patient 
organisations are benefiting from dedicated events, 
dedicated printed media and interaction through social 
media. We will present our findings to patients with ME/
CFS (eg, by direct communication with representative 
patient organisations and by giving talks to local associ-
ations of people with ME/CFS). General public will be 
reached through the COST Action website, oral presenta-
tions and interviews.
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